Last updated: October 2026

VO659 is an investigational antisense oligonucleotide from Vico Therapeutics designed to target the expanded CAG repeat associated with Huntington’s disease.

Current status

A Phase 1/2a study is evaluating VO659 with dosing schedules and safety as key early questions. This candidate is investigational and is not FDA approved. Timing, eligibility, safety, effectiveness, availability, and cost remain uncertain.

For the newest coverage across the HD treatment pipeline, visit What’s Happening in HD Treatment.